Business Wire

MDSLink Makes MaGiC™

25.1.2022 18:00:00 EET | Business Wire | Press release

Share

In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

MaGiC Small Form Factor Pluggable (Photo: Business Wire)

MaGiC-SFP 2.5™ (Multi-Gigabit Coax Small Form-factor Pluggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port).

Applications:

- Last 100-meter distribution using existing, in-building coax.

- Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul the traffic with MaGiC at speeds up to 2.5G in either direction.

- Hospitality/commercial wireless AP backhaul and powering. Using standalone power injectors, a single SFP/SFP+-based Ethernet switch combined with the MaGiC SFP can provide both data and power to remote APs in hallways, hotel rooms, public spaces and meeting rooms.

- Point-to-point (P2P), building-to-building or in-building. Using two media converters with two MaGiC SFP’s to deliver up to 2.5 Gbps over coax in a point-to-point setting.

MaGiC has a maximum packet error rate (PER) of 1e-6/1e-8 with a latency of six ms.

Channel stacking allows the delivery of up to 4 Gbps on a single coax wire by using high and low frequency MaGiC SFP’s.

Roadmap to the next generation MoCA Access 3.0 standard provides a smooth transition to 10 Gbps with backward interoperability with MoCA Access 2.5/2.0.

“Increasing the capacity of last mile data services is expensive. Existing solutions either call for new cable/fiber installation, or simply don’t meet the ever-increasing demand for bandwidth at reasonable prices increments," said Jim Luciano, president and founder of MDSLink.

MaGiC works in all telco/fiber, cable and satellite environments and is available now.

Contact the following distributors for more information including pricing: PCT International (Phoenix, AZ, https://www.pctinternational.com); SWG in Scranton, PA (https://swginc.com); GZT Telkom-Telmor Sp. z o.o., Gdansk, Poland, www.telmor.pl; and Heights Telecom www.heights-t.com, Tel Aviv, Israel.

About MDSLink

MDSLink, Inc., based in Bethlehem, PA, offers innovative products that help operators and integrators use existing, in-building wiring as the demand for high reliability and high bandwidth continues unabated. More information about the company and its products can be found at www.mdslink.com, or contact Jim Luciano, CEO, at jim.luciano@mdslink.com.

MaGiC and MaGiC SFP are trademarks of MDSLink, copyright 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rob Gelphman
MDSLink™
408-8387458
robert@gelphman.com
www.mdslink.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl

IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w

Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release

SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea

Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release

Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye